soul trial oral semaglutide cardiovascular outcomes 2024 results Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy Cardiovascular Outcomes, Safety, and Tolerability

Description

2 WhartonSLauDCWVallisMSharmaAMBierthoLCampbell-SchererDet al

Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial

JAMA Cardiol (2018) 3:280

weve all had it all along

Rather than pushing toward the maximum dose used in obesity trials, a clinician might: Start at a lower dose than usual Increase more slowly or pause increases for longer Stop escalating when acceptable appetite control and side-effect balance are reached, even if the dose is below the typical obesity dose This is where terms like microdosing guide and microdose guide show up online